LR-M for CT/MRI on LI-RADS v2018: a review of imaging criteria, performance, challenges and future directions from an end-user perspective
- PMID: 40810812
- DOI: 10.1007/s00261-025-05132-2
LR-M for CT/MRI on LI-RADS v2018: a review of imaging criteria, performance, challenges and future directions from an end-user perspective
Abstract
LR-M is a category within the Liver Imaging Reporting and Data System (LI-RADS) that refers to liver observations that are probably or definitely malignant but are not specific to hepatocellular carcinoma (HCC). It includes etiologies such as atypical HCC, intrahepatic cholangiocarcinoma, combined hepatocellular cholangiocarcinoma and metastases. The primary aim of LR-M is to ensure a high sensitivity for detecting all hepatic malignancies while preserving a high specificity for HCC in LR-5. The imaging criteria for LR-M encompass a variety of targetoid and non-targetoid features. LR-M is often less well understood by end-users compared to more prominent categories such as LR-4 and LR-5, which have garnered greater attention and familiarity. In this review written from an end-user perspective, we examine the critical role that LR-M plays within LI-RADS for CT/MRI, the prevalence of HCC and non-HCC malignancies in LR-M, and demonstrate how LR-M can impact prognosis and treatment outcomes. We discuss the current imaging criteria for LR-M and the challenges faced by end-users in LI-RADS v2018 for CT/MRI. Finally, we explore future directions for improving the application of LR-M in clinical practice.
Keywords: Combined hepatocellular cholangiocarcinoma; Computed tomography; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; LR-M; Liver imaging reporting and data system (LI-RADS); Magnetic resonance imaging.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma.Eur Radiol. 2025 Aug;35(8):4957-4966. doi: 10.1007/s00330-025-11418-2. Epub 2025 Feb 10. Eur Radiol. 2025. PMID: 39930127
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024: Category Redistribution and Short-Term Outcomes in Patients Undergoing 90Y Radioembolization for HCC.AJR Am J Roentgenol. 2025 Jul;225(1):e2532745. doi: 10.2214/AJR.25.32745. Epub 2025 Apr 30. AJR Am J Roentgenol. 2025. PMID: 40304670
-
A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.Diagnostics (Basel). 2022 Jul 7;12(7):1655. doi: 10.3390/diagnostics12071655. Diagnostics (Basel). 2022. PMID: 35885561 Free PMC article. Review.
-
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Cochrane Database Syst Rev. 2015. PMID: 26417712 Free PMC article.
References
-
- Kamaya A, Fetzer DT, Seow JH, Burrowes DP, Choi HH, Dawkins AA, Fung C, Gabriel H, Hong CW, Khurana A, McGillen KL, Morgan TA, Sirlin CB, Tse JR, Rodgers SK. LI-RADS US Surveillance Version 2024 for Surveillance of Hepatocellular Carcinoma: An Update to the American College of Radiology US LI-RADS. Radiology 2024;313(3):e240169. doi: https://doi.org/10.1148/radiol.240169 - DOI - PubMed
-
- Aslam A, Chernyak V, Tang A, Miller FH, Bashir M, Do R, Sirlin C, Lewandowski RJ, Kim CY, Kielar AZ, Kambadakone AR, Yarmohammadi H, Kim E, Owen D, Charalel RA, Shenoy-Bhangle A, Burke LM, Mendiratta-Lala M. CT/MRI LI-RADS 2024 Update: Treatment Response Assessment. Radiology 2024;313(2):e232408. doi: https://doi.org/10.1148/radiol.232408 - DOI - PubMed
-
- Lee S, Kim YY, Shin J, Hwang SH, Roh YH, Chung YE, Choi JY. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Journal of the American College of Radiology: JACR 2020;17(10):1199–1206. doi: https://doi.org/10.1016/j.jacr.2020.06.005
-
- American College of Radiology CT/MRI Liver Imaging Reporting and Data System version (2018). Available via https://www.acr.org / Clinical-Resources/Reporting-and-Data-Systems/ LI-RADS/CT-MRI-LI-RADS-v2018. Accessed 2021 15 April
-
- Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md) 2018;68(2):723–750. doi: https://doi.org/10.1002/hep.29913 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources